Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 6/20 | 0.33 |
| ▸ | NOS3 | P29474 | 5/20 | 0.33 |
| ▸ | NOS2 | P35228 | 5/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9626991 | 0.98 | CA1 (0.39) | CA1CA2CA4NOS1NOS3 | |
| SCHEMBL598869 | 0.78 | CA1 (0.46) | CA1CA2CA4NOS1NOS3 | |
| SCHEMBL4616915 | 0.78 | CA1 (0.46) | CA1CA2CA4NOS1NOS3 | |
| SCHEMBL6898227 | 0.78 | CA1 (0.46) | CA1CA2CA4NOS1NOS3 | |
| SCHEMBL23952890 | 0.78 | CA1 (0.46) | CA1CA2CA4NOS1NOS3 | |
| SCHEMBL283721 | 0.78 | CA1 (0.46) | CA1CA2CA4NOS1NOS3 | |
| SCHEMBL6250904 | 0.78 | CA1 (0.46) | CA1CA2CA4NOS1NOS3 | |
| SCHEMBL7724695 | 0.78 | CA1 (0.46) | CA1CA2CA4NOS1NOS3 | |
| SCHEMBL6894837 | 0.78 | CA1 (0.46) | CA1CA2CA4NOS1NOS3 | |
| SCHEMBL6897202 | 0.78 | CA1 (0.46) | CA1CA2CA4NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | CA1 4662/4885CA2 4663/4885CA4 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.